Amgen
Develops MariTide, a monthly antibody-peptide conjugate for obesity, alongside a broad biologics business.
Share price
$415
Up 41% over 12 monthsWhat analysts expect
Hold
Buy35%
Hold55%
Sell10%
Price target for the next 12 months
$388Down 8.7% compared with the current price
Price now $425Average targetLowest $200 to highest $500
30 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $38B
- Yearly profit
- $8.7B
- Company value
- $224B
Revenue and profit for the last twelve months reported.
Peptides in this book
- MariTideTrials only
Recent news
Risk in the news: CNBC reported that a failed Novartis Lp(a) drug trial raised doubts about the drug class, including Amgen's candidate.
Prices are delayed and figures rounded. Not investment advice.